Sana Biotechnology (NASDAQ:SANA) Shares Gap Down – Should You Sell?

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) gapped down before the market opened on Friday . The stock had previously closed at $3.25, but opened at $3.15. Sana Biotechnology shares last traded at $3.29, with a volume of 1,449,717 shares.

Analyst Upgrades and Downgrades

SANA has been the subject of several research reports. HC Wainwright increased their price objective on Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. JMP Securities cut Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. Finally, TD Cowen upgraded shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $14.25.

Sana Biotechnology Trading Down 2.3 %

The stock’s fifty day moving average is $2.42 and its two-hundred day moving average is $4.01. The firm has a market cap of $708.88 million, a P/E ratio of -2.28 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. On average, analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Insider Transactions at Sana Biotechnology

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the business’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the sale, the insider now directly owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 31.10% of the company’s stock.

Institutional Investors Weigh In On Sana Biotechnology

A number of hedge funds and other institutional investors have recently modified their holdings of SANA. Wilmington Savings Fund Society FSB bought a new stake in Sana Biotechnology in the third quarter valued at approximately $29,000. Stifel Financial Corp purchased a new position in shares of Sana Biotechnology during the 3rd quarter worth approximately $43,000. EP Wealth Advisors LLC bought a new position in shares of Sana Biotechnology in the 3rd quarter worth approximately $45,000. Blue Trust Inc. lifted its stake in shares of Sana Biotechnology by 1,246.6% in the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after purchasing an additional 12,154 shares during the period. Finally, Algert Global LLC bought a new stake in shares of Sana Biotechnology during the second quarter valued at approximately $73,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.